Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dialysis modalities and dyslipidemia.

Per-Ola Attman1, Ola Samuelsson, Ann-Cathrine Johansson

  • 1Department of Nephrology, Sahlgrenska University Hospital, Göteborg, Sweden. per-ola.attman@vgregion.se

Kidney International. Supplement
|April 16, 2003
PubMed
Summary

Kidney failure causes abnormal lipid profiles, increasing harmful lipoproteins. While hemodialysis offers moderate improvement, peritoneal dialysis worsens dyslipidemia, particularly cholesterol-rich lipoproteins.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospects for lithium treated patients with severe renal impairment.

International journal of bipolar disorders·2025
Same author

Lifetime risk of severe kidney disease in lithium-treated patients: a retrospective study.

International journal of bipolar disorders·2023
Same author

Effects of Steady Glucose Concentration Peritoneal Dialysis on Ultrafiltration Volume and Sodium Removal: A Pilot Crossover Trial.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Bioimpedance analysis in patients with chronic kidney disease.

Journal of renal care·2023
Same author

Factors associated with time to first dialysis-associated peritonitis episode: Data from the Peritonitis Prevention Study (PEPS).

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2023
Same author

The low risk for early renal damage during lithium treatment has not changed over time.

Journal of psychopharmacology (Oxford, England)·2022

Area of Science:

  • Nephrology
  • Lipid Metabolism
  • Cardiovascular Health

Background:

  • Progressive renal failure is linked to dyslipidemia, characterized by altered apolipoprotein profiles.
  • This dyslipidemia involves elevated levels of intact and partially metabolized triglyceride-rich apolipoprotein B (apoB)-containing lipoproteins.
  • Impaired metabolism and clearance contribute to the accumulation of these lipoproteins, particularly in very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) fractions.

Purpose of the Study:

  • To investigate the impact of different dialysis modalities on lipid profiles in patients with renal failure.
  • To characterize the specific changes in apolipoprotein profiles associated with progressive renal failure and its treatment.

Main Methods:

  • Analysis of apolipoprotein profiles in patients with progressive renal failure.

Related Experiment Videos

  • Comparison of lipid and apolipoprotein changes between hemodialysis and peritoneal dialysis patients.

    • Main Results:

    • Progressive renal failure is associated with increased concentrations of triglyceride-rich apoB-containing lipoproteins (VLDL and LDL).
    • Hemodialysis demonstrates a moderate attenuation of renal dyslipidemia.
    • Peritoneal dialysis is associated with a significant aggravation of dyslipidemia, including an increase in cholesterol-rich apoB-containing lipoproteins.

    Conclusions:

    • Renal failure significantly alters lipoprotein metabolism, leading to atherogenic dyslipidemia.
    • Dialysis modality influences the progression of dyslipidemia; hemodialysis offers partial benefit, while peritoneal dialysis exacerbates it.
    • Targeting lipoprotein abnormalities may be crucial for managing cardiovascular risk in dialysis patients.